Human interferon beta is a polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS). Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life.
- Mechanism
- Curator reviewed · 2 references
Part of the pathophysiology of MS is immune cell activation in addition to degradation of the blood–brain barrier (BBB), resulting in both neural demyelination and axon injury. Immunomodulating drugs such as interferon-beta decrease the inflammation that results in demyelination of nerves. Binding of interferon-beta to type 1 interferon receptors induces a series of beneficial transcriptional JAK/STAT pathway changes. This decreases antigen presentation as well as the proliferation of inflammatory T-cells, reducing the inflammation associated with MS. It also changes the expression of cytokine and matrix metalloproteinase (MMP).
- Primary indication
- This drug is indicated to treat relapsing forms of Multiple Sclerosis (MS) in adults, which includes clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.Curator reviewed · 1 structured indication
- Formula / weight
- 40036.0 Da
- Also known as
- Fibroblast interferon · FIF · Interferon beta · Interferon beta (human) · Interferon beta (recombinant)
- Code names
- SNG-001
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with Human interferon beta, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account